NIH Weekly Funding Opportunities and Policy Notices

Wednesday, February 3, 2021 - 9:43am
Notice NOT-LM-21-005 from the NIH Guide for Grants and Contracts
Wednesday, February 3, 2021 - 9:40am
Notice NOT-DA-21-018 from the NIH Guide for Grants and Contracts
Wednesday, February 3, 2021 - 9:34am
Notice NOT-CA-21-033 from the NIH Guide for Grants and Contracts
Wednesday, February 3, 2021 - 8:39am
Notice NOT-RM-21-012 from the NIH Guide for Grants and Contracts
Tuesday, February 2, 2021 - 12:38am
Notice NOT-NS-21-028 from the NIH Guide for Grants and Contracts
Tuesday, February 2, 2021 - 12:30am
Notice NOT-NS-21-027 from the NIH Guide for Grants and Contracts
Tuesday, February 2, 2021 - 12:15am
Notice NOT-OD-21-052 from the NIH Guide for Grants and Contracts
Tuesday, February 2, 2021 - 12:13am
Notice NOT-HD-21-005 from the NIH Guide for Grants and Contracts
Tuesday, February 2, 2021 - 12:11am
Funding Opportunity RFA-DA-22-004 from the NIH Guide for Grants and Contracts. This broad PAR will support exploratory studies addressing mechanistic questions in HIV infection, replication, latency, and/or pathogenesis (including HAND) in the context of SUDs.
Monday, February 1, 2021 - 9:08am
Funding Opportunity PAR-21-116 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA), utilizing the U24 grant funding mechanism, encourages applications for competing renewal of Data Coordinating Center (DCC) for ongoing clinical trials supported by NCCIH. Extension of an ongoing clinical trial will be supported when there is need for additional time to complete the trial or when an extended period of follow up is well justified to assess longer term outcomes. The DCC competing renewal application must propose a comprehensive plan for completion of the clinical trial data collection that provides overall project coordination and administrative; data management; and biostatistical support for the ongoing clinical trial. Both a DCC application and a corresponding Clinical Coordinating Center application can be submitted simultaneously for consideration by NCCIH if both are needed to complete the ongoing. If clinical trial data collection and follow up can be completed centrally by the DCC and no study visits at clinical sites are needed, a single application for competing renewal for the DCC can be submitted. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact for the ongoing clinical trial for which they are planning a competing renewal application prior to submitting to this FOA.
Monday, February 1, 2021 - 9:08am
Funding Opportunity PAR-21-117 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for competing renewal of Clinical Coordinating Center (CCC) for ongoing clinical trials supported by NCCIH; or competitive revisions to support ancillary studies to ongoing NCCIH supported clinical trials. Extension of an ongoing clinical trial will be supported when there is need for additional time to complete the trial or when an extended period of follow up is well justified to assess longer term outcomes. Competitive revisions will be supported when there is compelling justification for the addition of an ancillary study to an ongoing clinical trial. The objective of the Clinical Coordinating Center is to provide the design scientific rationale and a comprehensive scientific and operational plan for the clinical trial. The Clinical Coordinating Center is expected to be responsible for project management, participant recruitment and retention strategies, performance milestones, scientific conduct, and dissemination of results. Both a DCC application and a corresponding Clinical Coordinating Center application should be submitted simultaneously for consideration by NCCIH if both are needed to complete the ongoing clinical trial. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact for the ongoing clinical trial for which they are planning a competing renewal application or competitive revision prior to submitting to this FOA.
Monday, February 1, 2021 - 8:46am
Notice NOT-OD-21-048 from the NIH Guide for Grants and Contracts
Monday, February 1, 2021 - 8:12am
Notice NOT-NS-21-021 from the NIH Guide for Grants and Contracts
Monday, February 1, 2021 - 12:28am
Notice NOT-MH-21-160 from the NIH Guide for Grants and Contracts
Monday, February 1, 2021 - 12:19am
Funding Opportunity PAR-21-145 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites research projects that seek to model the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in health, illness, recovery, and overall wellbeing. Both animal and human subjects research projects are welcome. Researchers proposing basic science experimental studies involving human participants should consider this FOAs companion for basic experimental studies with humans.
Monday, February 1, 2021 - 12:18am
Funding Opportunity PAR-21-144 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing. Types of projects submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical and/or behavioral outcomes in humans to understand fundamental aspects of phenomena related to social connectedness and isolatedness. NIH considers such studies as prospective basic science studies involving human participants that meet the NIH definition of basic research and fall within the NIH definition of clinical trials (see, e.g., NOT-OD-19-024) Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind.

Pages